QC6352

New research indicates that QC6352, developed as a KDM4 inhibitor, acts primarily on DHODH, an enzyme involved in pyrimidine synthesis, when attacking glioblastoma stem cells. The finding reshapes understanding of how the compound kills these treatment-resistant cells and could guide future drug design for an aggressive brain cancer with few effective options. Researchers and oncology watchers are weighing the implications for therapy development.